Gennex Laboratories
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
Premier Fiscal Services Pvt Ltd, the promoter of Gennex Laboratories, has pledged 2.5 million shares to Vidya Tradecon Pvt Ltd for a business loan of ₹1.25 crore. The pledge was created on June 9, 2026, and expires on December 7, 2026. This brings the total promoter pledged shares to 12.5 million, or 23.57% of the promoter's holding of 53 million shares. The promoter group's overall stake in the company stands at 21.83% of the total equity. The shares were valued at ₹2.5 crore at the time of the pledge, providing a cover ratio of two times the loan amount. The company's stock closed at approximately ₹10 per share on the BSE.
Powered by Tijori
Premier Fiscal Services Pvt Ltd, the promoter of Gennex Laboratories, has pledged 2.5 million shares to Vidya Tradecon Pvt Ltd for a business loan of ₹1.25 crore. The pledge was created on June 9, 2026, and expires on December 7, 2026. This brings the total promoter pledged shares to 12.5 million, or 23.57% of the promoter's holding of 53 million shares. The promoter group's overall stake in the company stands at 21.83% of the total equity. The shares were valued at ₹2.5 crore at the time of the pledge, providing a cover ratio of two times the loan amount. The company's stock closed at approximately ₹10 per share on the BSE.
Powered by Tijori
Oct 28 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT ANDHRA PRADESH GOVERNMENT APPROVAL TO MANUFACTURE ADDITIONAL PRODUCTS
Source text: ID:nBSE5F4rKr
Further company coverage: GNXL.BO
(([email protected];;))
Oct 28 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT ANDHRA PRADESH GOVERNMENT APPROVAL TO MANUFACTURE ADDITIONAL PRODUCTS
Source text: ID:nBSE5F4rKr
Further company coverage: GNXL.BO
(([email protected];;))
Nov 29 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER FUNDRAISING BY WAY OF PREFERENTIAL ISSUE
Source text for Eikon: ID:nBSE4ndZ58
Further company coverage: GNXL.BO
(([email protected];))
Nov 29 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER FUNDRAISING BY WAY OF PREFERENTIAL ISSUE
Source text for Eikon: ID:nBSE4ndZ58
Further company coverage: GNXL.BO
(([email protected];))
Nov 20 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER PREFERENTIAL ISSUE OF SHARES TO SPECIFIC INDIVIDUALS AND ENTITIES
Source text for Eikon: ID:nBSEc4W2wz
Further company coverage: GNXL.BO
(([email protected];;))
Nov 20 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
TO CONSIDER PREFERENTIAL ISSUE OF SHARES TO SPECIFIC INDIVIDUALS AND ENTITIES
Source text for Eikon: ID:nBSEc4W2wz
Further company coverage: GNXL.BO
(([email protected];;))
June 1 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT RECEIVED LICENSE TO MANUFACTURE FOR SALE OF DRUGS FROM GOV OF ANDHRA PRADESH
Source text for Eikon: ID:nBSE4By8Zr
Further company coverage: GNXL.BO
(([email protected];))
June 1 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT RECEIVED LICENSE TO MANUFACTURE FOR SALE OF DRUGS FROM GOV OF ANDHRA PRADESH
Source text for Eikon: ID:nBSE4By8Zr
Further company coverage: GNXL.BO
(([email protected];))
May 31 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT CFO APPROVAL FROM POLLUTION CONTROL BOARD
Source text for Eikon: ID:nBSE5JbWx6
Further company coverage: GNXL.BO
(([email protected];))
May 31 (Reuters) - Gennex Laboratories Ltd GNXL.BO:
UNIT GOT CFO APPROVAL FROM POLLUTION CONTROL BOARD
Source text for Eikon: ID:nBSE5JbWx6
Further company coverage: GNXL.BO
(([email protected];))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Gennex Laboratories do?
Gennex Laboratories Ltd specializes in the production and export of bulk drugs and intermediates such as Guaiphenesin, Methocarbamol, Fluconazole, and Phenazopyridine.
Who are the competitors of Gennex Laboratories?
Gennex Laboratories major competitors are Ambalal Sarabhai Ent, Coral Laboratories, Brooks Laboratories, Lyka Labs, Vaidya Sane Ayur Lab, Achyut Healthcare, Panchsheel Organics. Market Cap of Gennex Laboratories is ₹225 Crs. While the median market cap of its peers are ₹212 Crs.
Is Gennex Laboratories financially stable compared to its competitors?
Gennex Laboratories seems to be less financially stable compared to its competitors. Altman Z score of Gennex Laboratories is 3.23 and is ranked 6 out of its 8 competitors.
Does Gennex Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Gennex Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Gennex Laboratories allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory, Short Term Loans & Advances
How strong is Gennex Laboratories balance sheet?
Balance sheet of Gennex Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Gennex Laboratories improving?
Yes, profit is increasing. The profit of Gennex Laboratories is ₹20.98 Crs for TTM, ₹18.12 Crs for Mar 2025 and ₹11.37 Crs for Mar 2024.
Is the debt of Gennex Laboratories increasing or decreasing?
Yes, The net debt of Gennex Laboratories is increasing. Latest net debt of Gennex Laboratories is -₹16.46 Crs as of Mar-26. This is greater than Mar-25 when it was -₹86.31 Crs.
Is Gennex Laboratories stock expensive?
Gennex Laboratories is not expensive. Latest PE of Gennex Laboratories is 10.75, while 3 year average PE is 28.14. Also latest EV/EBITDA of Gennex Laboratories is 7.7 while 3yr average is 18.18.
Has the share price of Gennex Laboratories grown faster than its competition?
Gennex Laboratories has given better returns compared to its competitors. Gennex Laboratories has grown at ~12.67% over the last 4yrs while peers have grown at a median rate of 0.82%
Is the promoter bullish about Gennex Laboratories?
Promoters seem to be bullish about the company. Latest quarter promoter holding is 23.63% and last quarter promoter holding is 23.62%.
Are mutual funds buying/selling Gennex Laboratories?
There is Insufficient data to gauge this.